GFM
GF Fund Management Portfolio holdings
AUM
$4.97B
This Quarter Return
-4%
1 Year Return
–
3 Year Return
–
5 Year Return
–
10 Year Return
–
AUM
$4.26B
AUM Growth
-$362M
(-7.8%)
Cap. Flow
-$2.11M
Cap. Flow
% of AUM
-0.05%
Top 10 Holdings %
Top 10 Hldgs %
43.71%
Holding
683
New
46
Increased
475
Reduced
93
Closed
17
Top Buys
| 1 |
Philip Morris
PM
|
$43M |
| 2 |
Amazon
AMZN
|
$24.3M |
| 3 |
Palantir
PLTR
|
$16.8M |
| 4 |
Yum China
YUMC
|
$14.4M |
| 5 |
Hims & Hers Health
HIMS
|
$10.9M |
Top Sells
| 1 |
Pinduoduo
PDD
|
$40.6M |
| 2 |
NVIDIA
NVDA
|
$25.7M |
| 3 |
KE Holdings
BEKE
|
$14.3M |
| 4 |
Meta Platforms (Facebook)
META
|
$13.3M |
| 5 |
Coca-Cola
KO
|
$9.83M |
Sector Composition
| 1 | Technology | 42.51% |
| 2 | Consumer Discretionary | 16.26% |
| 3 | Communication Services | 14.17% |
| 4 | Healthcare | 7.8% |
| 5 | Consumer Staples | 6.23% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
ORKA
576
Oruka Therapeutics, Inc. Common Stock
ORKA
$600M
| $9.19K | ﹤0.01% |
896
+161
| +22% | +$1.65K |
|
577
Altimmune
ALT
$322M
| $9.11K | ﹤0.01% |
1,821
+328
| +22% | +$1.64K |
|
578
Regenxbio
RGNX
$498M
| $9.07K | ﹤0.01% |
1,269
+229
| +22% | +$1.64K |
|
|
BFS
579
Saul Centers
BFS
$813M
| $9.02K | ﹤0.01% |
250
+11
| +5% | +$397 |
|
580
Stoke Therapeutics
STOK
$1.12B
| $9.01K | ﹤0.01% |
1,355
+243
| +22% | +$1.62K |
|
581
Galapagos
GLPG
$2.2B
| $8.97K | ﹤0.01% |
357
+64
| +22% | +$1.61K |
|
582
Entrada Therapeutics
TRDA
$208M
| $8.66K | ﹤0.01% |
958
+173
| +22% | +$1.56K |
|
583
Cartesian Therapeutics
RNAC
$278M
| $8.57K | ﹤0.01% |
650
+116
| +22% | +$1.53K |
|
|
OLP
584
One Liberty Properties
OLP
$511M
| $8.43K | ﹤0.01% |
321
+13
| +4% | +$342 |
|
585
Rigel Pharmaceuticals
RIGL
$727M
| $8.11K | ﹤0.01% |
451
+81
| +22% | +$1.46K |
|
586
Maravai LifeSciences
MRVI
$362M
| $8.03K | ﹤0.01% |
3,631
+653
| +22% | +$1.44K |
|
587
Pacific Biosciences
PACB
$375M
| $8.01K | ﹤0.01% |
6,791
+1,041
| +18% | +$1.23K |
|
|
AUTL
588
Autolus Therapeutics
AUTL
$381M
| $7.93K | ﹤0.01% |
5,113
+920
| +22% | +$1.43K |
|
589
Allogene Therapeutics
ALLO
$255M
| $7.84K | ﹤0.01% |
5,368
+965
| +22% | +$1.41K |
|
590
Astria Therapeutics
ATXS
$418M
| $7.71K | ﹤0.01% |
1,444
+259
| +22% | +$1.38K |
|
|
DHC
591
Diversified Healthcare Trust
DHC
$937M
| $7.58K | ﹤0.01% |
3,159
+123
| +4% | +$295 |
|
|
HPP
592
Hudson Pacific Properties
HPP
$1.12B
| $7.5K | ﹤0.01% |
2,541
+249
| +11% | +$735 |
|
593
Aura Biosciences
AURA
$405M
| $7.5K | ﹤0.01% |
1,279
+230
| +22% | +$1.35K |
|
594
OmniAb
OABI
$239M
| $7.44K | ﹤0.01% |
3,099
+558
| +22% | +$1.34K |
|
595
Absci
ABSI
$363M
| $7.38K | ﹤0.01% |
2,941
+529
| +22% | +$1.33K |
|
596
MaxCyte
MXCT
$147M
| $7.37K | ﹤0.01% |
2,701
+486
| +22% | +$1.33K |
|
597
Arcturus Therapeutics
ARCT
$496M
| $7.34K | ﹤0.01% |
693
+124
| +22% | +$1.31K |
|
598
Taysha Gene Therapies
TSHA
$911M
| $7.3K | ﹤0.01% |
5,248
+945
| +22% | +$1.31K |
|
599
Monte Rosa Therapeutics
GLUE
$308M
| $7.29K | ﹤0.01% |
1,572
+282
| +22% | +$1.31K |
|
600
Esperion Therapeutics
ESPR
$538M
| $7.27K | ﹤0.01% |
5,045
+908
| +22% | +$1.31K |
|